… with stage I–II non-small cell lung cancer (NSCLC) and has a … negative results of previous
lung cancer screening trials have … have been no previous systematic reviews of randomised …

… one narrative review on the subject [4, 10]. Accordingly, this systematic review was undertaken
to assess the survival of patients with a confirmed diagnosis of lung cancer without active …

… with completely resected non-small-cell lung cancer (NSCLC) remains unclear. We undertook
a systematic review and meta-analysis of the available evidence from randomised trials. …

… Improved understanding of the biology of lung cancer has … Systemic therapy for metastatic
non–small cell lung cancer is … with metastatic non–small cell lung cancer should undergo …

… improved survival for patients with non-small-cell lung cancer (NSCLC). We aimed to do
a systematic review and individual participant data meta-analysis to establish the effect of …

… This systematic review aimed to assess the clinical value of stereotactic body radiotherapy
(SABR) in patients with localized NSCLC on its own and in comparison with surgery and to …

… A pooled analysis showed that a positive family history of lung cancer predisposes
individuals to develop lung cancer 53 . Lung adenocarcinoma is more likely to have a genetic …

… in this systematic review are objective in nature (eg, 5-year survival) and are not likely to be
influenced by performance or detection bias. Visual inspection of funnel plots found no clear …

… In the decade since the last Lancet Seminar on lung cancer there have been advances in
many aspects of the classification, diagnosis, and treatment of non-small-cell lung cancer (…

… In conclusion, the information provided with our systematic review gives a potential picture
of lung cancer patients with PD-L1 expression ≥ 5%. Overall, there are no clear distinctive …